Absorbing Declines in Product Prices and Achieving Stable Growth
First written in FY2016. 29 of 37 entries say "Advanced", first in FY2017-Q1. Latest entry: 2026-07-30.
No other company in this theme has enough history to compare yet.
- FY2026-H1AdvancedAnnual report
「The June 2024 reimbursement price revision resulted in a two-month year-on-year impact from lower selling prices, but this was offset by higher sales volumes in the core and growth businesses.」
With the impact of lower unit prices following the June 2024 reimbursement price revision still present, higher sales volumes offset the impact, resulting in revenue of ¥29,285 million for the interim period, up 4.6% year on year. - FY2025AdvancedAnnual report
「Although selling prices declined across many product categories following the reimbursement price revision, the core business and new areas within the growth businesses generally performed well. The resulting increase in sales volumes offset the impact.」
The decline in unit prices following the June 2024 price revision was offset by higher sales volumes, resulting in revenue of ¥56,610 million, up 10.2% year on year, and operating profit of ¥12,326 million, up 13.2%. - FY2025-H1AdvancedAnnual report
「As a result, the Company achieved substantial increases in both revenue and profit after offsetting the negative impact of the June 2024 reimbursement price revision.」
The negative impact of the reimbursement price revision was offset, with revenue increasing 11.4% year on year and operating profit increasing 14.4%. - FY2024-Q3Revenue down, profit up continuesAnnual report
「As a result, although revenue for the cumulative third quarter of the current consolidated fiscal year declined 0.5% year on year, gross profit increased 5.3%, absorbing the increase in selling, general and administrative expenses, and each profit level below gross profit increased.」
Revenue declined 0.5% year on year, while gross profit increased 5.3% and operating profit increased 6.5%. Profitability continued to improve despite the decline in revenue. - FY2024-Q2Lower Sales, Higher ProfitAnnual report
「As a result, although revenue for the cumulative second quarter of the current consolidated fiscal year declined 1.4% year on year, growth in gross profit absorbed the increase in selling, general and administrative expenses. Each level of profit increased year on year, and all profit margins improved.」
Revenue declined 1.4% year on year, while gross profit increased 4.7% and operating profit increased 6.9%, with profit margins also improving. - FY2024-Q1AdvancedAnnual report
「Operating profit was ¥7,887 million, an increase of ¥428 million from the same period of the previous year. Revenue from the Company’s products increased due to a higher number of AF procedures, while revenue from purchased products declined following a change in the distribution channel for RF Needle. As a result, the Company’s product ratio rose 5.2 percentage points year on year to 59.8%. In addition, inventory disposal and valuation losses declined by ¥118 million from the same period of the previous year. Consequently, the gross profit margin rose 3.4 percentage points year on year to 60.9%.」
While revenue declined 0.1% year on year, gross profit increased 5.8%, the gross profit margin rose 3.4 percentage points and the operating profit margin rose 3.6 percentage points. Profitability improved through the product mix and other factors amid changes in pricing and distribution channels. - FY2023AdvancedAnnual report
「The gross profit margin rose 1.8 percentage points from the previous fiscal year to 57.8%. The main reasons were a ¥1,413 million year-on-year reduction in losses on the disposal and valuation of inventories, including product and merchandise inventories and raw materials, and a 2.5 percentage point increase in the Company’s product ratio to 54.9%. These factors absorbed the negative impact of the deterioration in the gross profit margin accompanying the reimbursement price revision and lower sales volumes of certain products.」
Negative impacts from falling reimbursement prices and other factors were absorbed through a higher Company product ratio and lower inventory disposal and valuation losses, improving the gross profit margin to 57.8% and the operating profit margin to 20.9%. - FY2023-Q3Lower Sales, Higher ProfitAnnual report
「Revenue was ¥38,498 million, a decrease of ¥511 million from the same period of the previous year. Gross profit was ¥22,140 million, an increase of ¥383 million from the same period of the previous year. Operating profit was ¥7,931 million, an increase of ¥426 million from the same period of the previous year.」
Cumulative third-quarter revenue declined 1.3% year on year, while gross profit increased 1.8% and operating profit increased 5.7%, showing lower revenue alongside improved profitability. - FY2023-Q2AdvancedAnnual report
「Revenue was ¥25,489 million, an increase of ¥358 million from the same period of the previous year. Operating profit was ¥5,119 million, an increase of ¥437 million from the same period of the previous year.」
Despite continuing reimbursement price reductions, cumulative second-quarter revenue increased 1.4% year on year, while operating profit increased 9.4%. - FY2023-Q1AdvancedAnnual report
「Revenue was ¥12,969 million, an increase of ¥356 million from the same period of the previous year. Despite the impact of the reimbursement price revision, the ratio of the Company’s products rose 3.2 percentage points from the same period of the previous year to 54.6%. As a result, the gross profit margin was 57.5%, down 0.2 percentage points from the same period of the previous year. Operating profit was ¥2,707 million, an increase of ¥387 million from the same period of the previous year.」
Despite downward pressure from the April 2022 reimbursement price revision, the Company’s product ratio rose 3.2 percentage points to 54.6%, while revenue increased 2.8% and operating profit increased 16.7% year on year. - FY2022Flat net sales and lower operating profitAnnual report
「Accordingly, revenue for the fiscal year was ¥51,469 million, up 0.4% year on year. Accordingly, operating profit for the fiscal year was ¥9,973 million, down 3.8% year on year.」
Revenue increased just 0.4% year on year, while operating profit declined 3.8%, indicating deterioration in profitability amid stable growth accompanied by higher revenue. - FY2022-Q3Revenue up, but operating profit slightly lowerAnnual report
「Accordingly, revenue for the cumulative third quarter of the current consolidated fiscal year was ¥39,009 million, up 1.8% year on year. Accordingly, operating profit for the cumulative third quarter of the current consolidated fiscal year was ¥7,504 million, down 0.1% year on year.」
Cumulative third-quarter revenue increased 1.8% year on year, while operating profit declined 0.1%, showing continued growth alongside a slight decline in profit. - FY2022-Q2AdvancedAnnual report
「Accordingly, revenue for the cumulative second quarter of the current consolidated fiscal year was ¥25,130 million, up 2.8% year on year.」
Cumulative quarterly revenue increased 2.8% year on year despite the resurgence of COVID-19 infections and continued restrictions on procedures. Operating profit was also ¥4,681 million, up 7.2% year on year. - FY2022-Q1AdvancedAnnual report
「Accordingly, revenue for the cumulative first quarter of the current consolidated fiscal year was ¥12,612 million, up 10.0% year on year.」
Despite the continuing impact of COVID-19, first-quarter revenue increased 10.0% year on year, demonstrating growth despite falling prices. - FY2021WorsenedAnnual report
「Accordingly, revenue for the fiscal year was ¥51,286 million, down 0.9% year on year.」
Following reimbursement price reductions and a decline in procedure volumes due to COVID-19, revenue declined 0.9% year on year, while still indicating stable growth despite falling prices. - FY2021-Q3AdvancedAnnual report
「Accordingly, revenue for the cumulative third quarter of the current consolidated fiscal year was ¥38,328 million, up 0.8% year on year.」
Despite the impact of the April 2020 reimbursement price reduction and a decline in procedure volumes due to COVID-19, cumulative quarterly revenue increased 0.8% year on year. - FY2021-Q2AdvancedAnnual report
「Accordingly, revenue for the cumulative second quarter of the current consolidated fiscal year was ¥24,453 million, up 1.2% year on year.」
Cumulative quarterly revenue increased 1.2% year on year despite COVID-19, reimbursement price reductions and declines in revenue from certain product categories. Operating profit also exceeded the plan. - FY2021-Q1WorsenedAnnual report
「Accordingly, revenue for the cumulative first quarter of the current consolidated fiscal year was ¥11,468 million, down 2.7% year on year.」
The postponement of procedures due to COVID-19 and reimbursement price reductions resulted in a 2.7% year-on-year decline in quarterly revenue, indicating short-term deterioration in stable growth under falling prices. - FY2020AdvancedAnnual report
「Revenue for the fiscal year was ¥51,761 million, up 13.7% year on year.」
Despite reimbursement price reductions and changes in the product mix, revenue for the fiscal year increased 13.7% year on year. Operating profit, however, declined 0.9% year on year. - FY2020-Q3AdvancedAnnual report
「Accordingly, revenue for the cumulative third quarter of the current consolidated fiscal year was ¥38,017 million, up 12.6% year on year.」
Cumulative third-quarter revenue increased 12.6% year on year, sustaining revenue growth despite price revisions and changes in the product mix. Operating profit, however, declined 0.9% year on year. - FY2020-Q2AdvancedAnnual report
「Strong sales of BSC’s S-ICD, which was introduced ahead of schedule in April 2019, and growth in purchased products following the start of full-scale sales of the company’s products in September resulted in operating profit for the cumulative second quarter of the current consolidated fiscal year of ¥4,851 million, exceeding the plan and down 0.2% year on year.」
Against a backdrop of expanding sales of BSC’s S-ICD and CRM products, cumulative quarterly revenue was ¥24,173 million, up 8.6% year on year, while operating profit was ¥4,851 million, exceeding the plan. - FY2020-Q1AdvancedAnnual report
「Accordingly, revenue for the cumulative first quarter of the current consolidated fiscal year was ¥11,785 million, up 6.6% year on year.」
First-quarter revenue increased 6.6% year on year, driven in part by the contribution of new products. Operating profit also exceeded the plan, demonstrating growth despite the pricing and earnings environment. - FY2019AdvancedAnnual report
「Revenue for the fiscal year was ¥45,525 million, up 7.6% year on year.」
Despite reimbursement price reductions and the impact of certain competitors, revenue increased 7.6% year on year, supported by new products and the Company’s products in EP/ablation, surgery-related products and intervention. - FY2019-Q3AdvancedAnnual report
「In addition to the impact of the April 2018 revision of reimbursement prices for medical devices, sales of existing products in the rhythm devices category declined following the announcement of a change in suppliers. However, revenue increased year on year in the other product categories, supported by the contribution of the Company’s products and newly introduced products. Accordingly, revenue for the cumulative third quarter of the current consolidated fiscal year was ¥33,757 million, up 8.4% year on year.」
Despite the impact of the reimbursement price revision and lower sales of certain products, revenue increased 8.4% year on year, supported by the contribution of the Company’s products and new products, sustaining growth despite falling prices. - FY2019-Q2AdvancedAnnual report
「Accordingly, revenue for the cumulative second quarter of the current consolidated fiscal year was ¥22,265 million, up 9.9% year on year.」
The impact of price reductions was absorbed through higher sales volumes of existing products and the launch of new products, resulting in a 9.9% year-on-year increase in cumulative quarterly revenue. Operating profit was ¥4,860 million, exceeding the plan. - FY2019-Q1AdvancedAnnual report
「Although the April revision of reimbursement prices lowered prices across our product portfolio, higher sales volumes of existing products and the introduction of new products offset the impact of the price reductions, resulting in higher sales.」
While reimbursement prices were reduced across the board, higher volumes of existing products and the introduction of new products offset the impact, with sales up 8.1% year on year. - FY2018AdvancedAnnual report
「As a result, sales for the fiscal year were ¥42,298 million, up 13.8% from the previous fiscal year.」
Sales for the fiscal year were ¥42,298 million, up 13.8% from the previous fiscal year. The gross profit margin also improved 3.6 percentage points due to growth in sales of highly profitable products, among other factors, while operating profit increased 38.9% from the previous fiscal year. - FY2018-Q3AdvancedAnnual report
「In addition to growth in sales of highly profitable products, both sourced and our own, the gross profit margin improved 3.7 percentage points year on year due in part to adjustments for unrealized gains associated with the absorption merger of a consolidated subsidiary effective 1 April last year.」
The gross profit margin improved 3.7 percentage points due to growth in sales of highly profitable sourced products and our own products, among other factors, while operating profit increased 41.9% year on year. - FY2018-Q2AdvancedAnnual report
「The second quarter of the fiscal year coincided with the concentrated timing of major conferences related to our business areas, and an impact on sales had been expected. However, actual results exceeded the initial plan in every product category. As a result, sales for the six months ended 30 September were ¥20,267 million, up 13.4% year on year.」
Despite the expected impact on sales from the concentration of major conferences, results exceeded the initial plan in every product category, and sales increased 13.4% year on year. - FY2018-Q1AdvancedAnnual report
「As a result, sales for the three months ended 30 June were ¥10,228 million, up 14.9% year on year.」
Quarterly sales increased 14.9% year on year, demonstrating progress toward stable growth. - FY2017AdvancedAnnual report
「In terms of profit, despite the revision of reimbursement prices, the gross profit margin improved 2.7 percentage points from the previous fiscal year due to lower costs for our own products and a higher sales mix of highly profitable new sourced products.」
Despite lower reimbursement prices, the gross profit margin improved 2.7 percentage points due to lower costs for our own products and a higher sales mix of highly profitable new products. - FY2017-Q3AdvancedAnnual report
「Although the revision of reimbursement prices for medical devices implemented in April last year reduced prices for most of the products we handle, the impact on performance was limited compared with previous price revisions because price reductions for one-of-a-kind products and other products with a high contribution to performance were smaller, and our key products have shifted to new products in functional categories with high reimbursement prices. As a result, sales for the nine months ended 31 December were ¥27,264 million, up 25.6% from the same period of the previous year.」
Sales have continued to increase while the impact of price reductions has been limited by one-of-a-kind products and the shift to new products with high reimbursement prices. - FY2017-Q2AdvancedAnnual report
「Although prices were reduced for most of the products we handle, the impact on performance was limited compared with previous price revisions because price reductions for one-of-a-kind products and other products with a high contribution to performance were smaller, and our key products have shifted to new products in functional categories with high reimbursement prices.」
The impact of price reductions was limited by containing declines in prices for one-of-a-kind products and shifting to new products with high reimbursement prices, with cumulative sales up 28.0% year on year. - FY2017-Q1AdvancedAnnual report
「As a result, sales for the three months ended 30 June were ¥8,905 million, up 32.0% year on year.」
Despite lower reimbursement prices, quarterly sales increased 32.0% year on year. - FY2016First statedAnnual report
「With further product price declines expected, the challenge is how to absorb their impact and achieve stable growth.」
The company has identified achieving stable growth in an environment of declining prices as a key challenge.